Glenview Capital Management
VC Fund
New York, United States
Glenview Capital Management is a hedge fund founded in 2000 with approximately $9.2 billion of capital under management.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Glenview Capital Management invests in
Stages Glenview Capital Management invests in
Countries Glenview Capital Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dennis Chao
|
|||
Larry Robbins
|
|||
|
Lee Hathaway
|
|||
Investment Focus
Industry
- Health Care 6 (55%)
- Medical 3 (27%)
- Medical Device 3 (27%)
- Manufacturing 2 (18%)
- Semiconductor 2 (18%)
Stage
- Post-IPO Equity 3 (27%)
- Series D 2 (18%)
- Series A 1 (9%)
- Series B 1 (9%)
- Series C 1 (9%)
Country
- United States 7 (64%)
- United Kingdom 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dennis Chao
Senior Analyst - Therapeutics
|
Senior Analyst - Therapeutics | Total investments: 0 | Find email | |
|
Larry Robbins
Founder and CEO
|
Founder and CEO | Total investments: 1 | Find email | |
|
Lee Hathaway
Partner, Co-Head of Healthcare at Glenview Capital
|
Partner, Co-Head of Healthcare at Glenview Capital | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Quanta
|
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $60M / Series E / Nov 18, 2024 | |
Detect
|
Detect they build tools that empower people to understand their health. | Series C / Nov 15, 2022 | |
Limber
|
Limber Health is enabling the delivery of the world’s leading hybrid model of in-person and digital musculoskeletal (MSK) care. Developed by physical therapists and physicians, Limber Health empowers providers with a complete digital toolkit for Remote Therapeutic Monitoring (RTM), Home Exercise Programs (HEP), Outcomes Collection, MIPS Reporting,and the shift to value-based care. Clinically validated through research conducted at Mayo Clinic and awarded Most Impactful New Technology by the American Congress of Rehabilitation Medicine, Limber empowers providers in augmenting in-person clinician visits with digital at-home support to best meet patients where they are. | $16M / Series A / Oct 20, 2022 | |
|
Limber
|
Limber Health is enabling the delivery of the world’s leading hybrid model of in-person and digital musculoskeletal (MSK) care. Developed by physical therapists and physicians, Limber Health empowers providers with a complete digital toolkit for Remote Therapeutic Monitoring (RTM), Home Exercise Programs (HEP), Outcomes Collection, MIPS Reporting,and the shift to value-based care. Clinically validated through research conducted at Mayo Clinic and awarded Most Impactful New Technology by the American Congress of Rehabilitation Medicine, Limber empowers providers in augmenting in-person clinician visits with digital at-home support to best meet patients where they are. | $16M / Series A / Oct 20, 2022 | |
|
Quanta
|
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $245M / Series D / Jun 23, 2021 | |
Quantum SI
|
Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what hasbeen possible with DNA sequencing. | $425M / Post-IPO Equity / Jun 11, 2021 | |
Tesseract Health
|
Identifeye is creating prediction models that combine multiple retinal imaging modalities with expert annotations to create comprehensive and non-invasive health assessments. Identifeye Health is a part of the 4Catalyzer accelerator, which is dedicated to improving patient care globally. It has offices in Guilford, Connecticut, New York City, andPalo Alto, California. | $80M / Series B / Apr 20, 2021 | |
|
Tesseract Health
|
Identifeye is creating prediction models that combine multiple retinal imaging modalities with expert annotations to create comprehensive and non-invasive health assessments. Identifeye Health is a part of the 4Catalyzer accelerator, which is dedicated to improving patient care globally. It has offices in Guilford, Connecticut, New York City, andPalo Alto, California. | $80M / Series B / Apr 20, 2021 | |
Butterfly Network
|
Butterfly has created the world's first handheld, single-probe whole-body ultrasound system using its patented Ultrasound-on-Chip™ semiconductor technology. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, including for the 4.7 billion people around the world lacking access toultrasound. Butterfly is paving the way for earlier detection and remote management of health conditions around the world. | $175M / Post-IPO Equity / Feb 16, 2021 | |
SunEdison
|
SunEdison is your trusted partner for innovative, intelligent energy solutions around the globe. We have built our business by putting our customers first, and focusing on addressing each customer's unique solar energy needs. Through our integrated service approach, we partner with you, help you navigate your way through the solar landscapeand offer uniquely tailored solutions and flexible financing. | $402.5M / Post-IPO Equity / Jun 16, 2015 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Glenview Capital Management invest in?
Glenview Capital Management invests primarily in Health Care, Medical and Medical Device startups, most often at Post-IPO Equity and Series D stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Glenview Capital Management?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Glenview Capital Management?
The team at Glenview Capital Management includes Dennis Chao (Senior Analyst - Therapeutics), Larry Robbins (Founder and CEO) and Lee Hathaway (Partner, Co-Head of Healthcare at Glenview Capital). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
